litlas
Log inCreate account

Brian G. Feagan

Active 1993–2025

Also published as
Brian G Feagan
364
Papers
83,992
Citations
137
h-index
342
i10-index

Citations

Citations per year for Brian G. Feagan1982: 1 citations1991: 6 citations1993: 8 citations1994: 3 citations1995: 13 citations1996: 15 citations1997: 21 citations1998: 22 citations1999: 43 citations2000: 44 citations2001: 59 citations2002: 110 citations2003: 135 citations2004: 168 citations2005: 184 citations2006: 304 citations2007: 345 citations2008: 359 citations2009: 399 citations2010: 474 citations2011: 508 citations2012: 417 citations2013: 624 citations2014: 752 citations2015: 799 citations2016: 774 citations2017: 997 citations2018: 1,023 citations2019: 3,414 citations2020: 3,402 citations2021: 2,909 citations2022: 2,620 citations2023: 2,440 citations2024: 3,589 citations2025: 1,751 citations2026: 42 citations1983–1990: no citations, so these years are not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,305 citing papers, 20.5% of this breakdownUnited Kingdom: 1,630 citing papers, 7.7% of this breakdownCanada: 1,474 citing papers, 7% of this breakdownChina: 1,456 citing papers, 6.9% of this breakdownItaly: 1,303 citing papers, 6.2% of this breakdownFrance: 1,101 citing papers, 5.2% of this breakdownGermany: 1,062 citing papers, 5% of this breakdownNetherlands: 833 citing papers, 4% of this breakdownBelgium: 743 citing papers, 3.5% of this breakdownSpain: 675 citing papers, 3.2% of this breakdownJapan: 600 citing papers, 2.9% of this breakdownAustralia: 554 citing papers, 2.6% of this breakdown
0%20.5%Other 25.3%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology56.9%
  • Medicine27.9%
  • Immunology and Microbiology9.6%
  • Neuroscience1.2%
  • Nursing1%
  • Agricultural and Biological Sciences0.7%
  • Other2.7%

Topics

  • Inflammatory Bowel Disease20.6%
  • Microscopic Colitis6.9%
  • Rheumatoid Arthritis Research and Therapies4.1%
  • Gut microbiota and health3.4%
  • Autoimmune and Inflammatory Disorders3.1%
  • Biosimilars and Bioanalytical Methods2.4%
  • Other59.5%

Coauthors

All papers

Open in search
  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio Danese, Irving H. Fox, Catherine Milch, Serap Sankoh, Tim Wyant, Jing Xu, Asit Parikh - New England Journal of Medicine 2013 cited by 2,852

  2. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: William J. Sandborn, Chinyu Su, Bruce E. Sands, Geert D’Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G. Feagan, Walter Reinisch, Wojciech Niezychowski, Gary S. Friedman, Nervin Lawendy, Dahong Yu, Deborah Woodworth, Arnab Mukherjee, Haiying Zhang, Paul J. Healey, Julián Panés - New England Journal of Medicine 2017 cited by 1,727

  3. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

    Authors: Brian G. Feagan, William J. Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R. Friedman, Marion Blank, Jewel Johanns, Long-Long Gao, Miao Ye, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B. Hanauer, Séverine Vermeire, Stephan R. Targan, Subrata Ghosh, Willem J. de Villiers, Jean–Frédéric Colombel, Zsolt Tulassay, Ursula Seidler, Bruce Salzberg, Pierre Desreumaux, Scott D. Lee, Edward V. Loftus, Levinus A. Dieleman, Seymour Katz, Paul Rutgeerts - New England Journal of Medicine 2016 cited by 1,806

  4. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    Authors: William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Stephen B. Hanauer, Jean‐Frédéric Colombel, Bruce E. Sands, Milan Lukáš, Richard N. Fedorak, Scott Lee, Brian Bressler, Irving H. Fox, Maria Rosario, Serap Sankoh, Jing Xu, Kristin Stephens, Catherine Milch, Asit Parikh - New England Journal of Medicine 2013 cited by 2,687

  5. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel - New England Journal of Medicine 2005 cited by 3,883

  6. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

    Authors: William J. Sandborn, Séverine Vermeire, Laurent Peyrin‐Biroulet, Marla C. Dubinsky, Julián Panés, Andrés Yarur, Timothy E. Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert D’Haens, Silvio Danese, Martina Goetsch, Brian G. Feagan - The Lancet 2023 cited by 333

  7. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis

    Authors: William J. Sandborn, Brian G. Feagan, Geert D’Haens, Douglas C. Wolf, Igor Jovanović, Stephen B. Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y. Hua, Ji Hwan Lee, Lorna Charles, Denesh K. Chitkara, Keith Usiskin, Jean–Frédéric Colombel, Loren Laine, Silvio Danese - New England Journal of Medicine 2021 cited by 532

  8. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

    Authors: Geert D’Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Marc Ferrante - The Lancet 2022 cited by 387

  9. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    Authors: Laurent Peyrin‐Biroulet, William J. Sandborn, Bruce E. Sands, Walter Reinisch, Willem A. Bemelman, Robert V. Bryant, Geert D’Haens, Iris Dotan, Marla C. Dubinsky, Brian G. Feagan, Gionata Fiorino, Richard B. Gearry, Suneeta Krishnareddy, Péter L. Lakatos, Edward V. Loftus, Philippe Marteau, Pia Munkholm, Travis B. Murdoch, Íngrid Ordás, Remo Panaccione, Robert H. Riddell, Joannie Ruel, David T. Rubin, Mark Samaan, Corey A. Siegel, Mark S. Silverberg, Jaap Stoker, S Schreiber, Simon Travis, Gert Van Assche, Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 cited by 1,838

  10. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

    Authors: Brian G. Feagan, Silvio Danese, Edward V. Loftus, Séverine Vermeire, Stefan Schreiber, Timothy E. Ritter, Ronald Fogel, Rajiv Mehta, Sandeep Nijhawan, Radosław Kempiński, Rafał Filip, Ihor Hospodarskyy, Ursula Seidler, Frank Seibold, Ian Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chia‐Hsiang Hsueh, Chantal Tasset, R. Besuyen, Mamoru Watanabe, William J. Sandborn, Gerhard Rogler, Toshifumi Hibi∥, Laurent Peyrin‐Biroulet - The Lancet 2021 cited by 437

  11. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

    Authors: Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean–Frédéric Colombel, Silvio Danese, Marla C. Dubinsky, Brian G. Feagan, Tadakazu Hisamatsu, Allen Lim, James O. Lindsay, Edward V. Loftus, Julián Panés, Laurent Peyrin‐Biroulet, Zhihua Ran, David T. Rubin, William J. Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W. Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D’Haens - The Lancet 2022 cited by 316

  12. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

    Authors: Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter Higgins, Jan Wehkamp, Brian G. Feagan, Michael Yao, Marek Karczewski, Jacek Karczewski, Nicole Pezous, Stephan Bek, Gerard Bruin, Bjoern Mellgard, C Berger, Marco Londei, Arthur P. Bertolino, Gervais Tougas, Simon Travis, for the Secukinumab in Crohn's Disease Study Group - Gut 2012 cited by 1,495

  13. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

    Authors: Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, Lloyd Mayer, Stefan Schreiber, Jean‐Frédéric Colombel, Daniel Rachmilewitz, Douglas C. Wolf, Allan Olson, Weihang Bao, Paul Rutgeerts - The Lancet 2002 cited by 4,163

  14. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

    Authors: Brian G. Feagan, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés, Tkachev Av, Dilara Kalimullina, Robert Petryka, М. Ф. Осипенко, Nataliia Tsarynna, Leonid Bilіanskyi, D Kleczkowski, Andrii Yurkiv, Marek Woynarowski, О. Аbrahamovych, Olha Ivanishyn, Grażyna Rydzewska, Jarosław Kierkuś, Elina Petrova, Olga Vasilevskaya, Halyna Afanasieva, Carlos Fernando de Magalhães Francesconi, Jarosław Leszczyszyn, Elena Bunkova, Dmitry Platonov, Olena Datsenko, Oleksii Gridnyev, Ihor Hospodarsky, Liudmyla Nykodymivna Prystupa, Mykola Stanislavchuk, Anatoly Pershko, О. Б. Щукина, В. И. Симаненков, Oleksandr Golovchenko, William Holderman, Juan S. Lasa, Jakob Begun, Maria de Lourdes de Abreu Ferrari, Pedro López, A. A. Obrezan, Shiraz Farooq, Felix Tiongco, Abel Novillo, Emiliano Tron, Finlay Macrae, Rupert W. Leong, Lígia Yukie Sassaki, Cyrla Zaltman, Roberto Luiz Kaiser, Andreas Stallmach, Jochen Klaus, Manuel Martı́nez, Azalia Ruiz, Р А Абдулхаков, Vishvinder Sharma, Louis Y Korman, James D. Lord, Bhaktasharan Patel, Timothy E. Ritter - ˜The œLancet. Gastroenterology & hepatology 2023 cited by 224

  15. Gut Microbiome Composition Is Associated With Future Onset of Crohn’s Disease in Healthy First-Degree Relatives

    Authors: Juan A. Raygoza Garay, Williams Turpin, Sun-Ho Lee, Michelle I. Smith, Ashleigh Goethel, Anne M. Griffiths, Paul Moayyedi, Osvaldo Espin‐Garcia, Maria Abreu, Guy Aumais, Çharles N. Bernstein, I Avni Biron, Maria Cino, Colette Deslandres, Iris Dotan, Wael El-Matary, Brian G. Feagan, David S. Guttman, Hien Q. Huynh, Levinus A. Dieleman, Jeffrey S. Hyams, Kevan Jacobson, David Mack, John K. Marshall, Anthony Otley, Remo Panaccione, Mark J. Ropeleski, Mark S. Silverberg, A. Hillary Steinhart, Dan Turner, Baruch Yerushalmi, Andrew D. Paterson, Wei Xu, Maria Abreu, Paul L. Beck, Çharles N. Bernstein, Kenneth Croitoru, Levinus A. Dieleman, Brian G. Feagan, Anne M. Griffiths, David S. Guttman, Kevan Jacobson, Gilaad G. Kaplan, Denis O. Krause, Karen Madsen, John K. Marshall, Paul Moayyedi, Mark J. Ropeleski, Ernest G. Seidman, Mark S. Silverberg, Scott B. Snapper, Andy Stadnyk, Hillary Steinhart, Michael G. Surette, Dan Turner, Tom Walters, Bruce A. Vallance, Guy Aumais, Alain Bitton, Maria Cino, Jeff Critch, Lee A. Denson, C Deslandres, Wael El-Matary, Hans Herfarth, Peter Higgins, Hien Q. Huynh, Jeffrey S. Hyams, David Mack, Jerry McGrath, Anthony Otley, Remo Panancionne, Kenneth Croitoru - Gastroenterology 2023 cited by 192

  16. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

    Authors: Bram Verstockt, Azucena Salas, Bruce E. Sands, Clara Abraham, Haim Leibovitzh, Markus F. Neurath, Niels Vande Casteele, Silvio Danese, Geert D’Haens, Lars Eckmann, William A. Faubion, Brian G. Feagan, Vipul Jairath, Christopher Ma, Saurabh Mehandru, Julián Panés, Florian Rieder, William J. Sandborn, Mark S. Silverberg, Marisol Veny, Séverine Vermeire, Stefania Vetrano - Nature Reviews Gastroenterology & Hepatology 2023 cited by 231

  17. Global burden of inflammatory bowel disease

    Authors: Vipul Jairath, Brian G. Feagan - ˜The œLancet. Gastroenterology & hepatology 2019 cited by 363

  18. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    Authors: William J. Sandborn, Brian G. Feagan, Colleen Marano, Hongyan Zhang, Richard Strauß, Jewel Johanns, Omoniyi J. Adedokun, Cynthia Guzzo, Jean‐Frédéric Colombel, Walter Reinisch, Peter R. Gibson, Judith Collins, Gunnar Järnerot, Toshifumi Hibi∥, Paul Rutgeerts - Gastroenterology 2013 cited by 928

  19. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

    Authors: William J. Sandborn, Brian G. Feagan, Edward V. Loftus, Laurent Peyrin‐Biroulet, Gert Van Assche, Geert D’Haens, Stefan Schreiber, Jean‐Frédéric Colombel, James D. Lewis, Subrata Ghosh, Alessandro Armuzzi, Ellen Scherl, Hans Herfarth, L.M. Vitale, Mohamed‐Eslam F. Mohamed, Ahmed A. Othman, Qian Zhou, Bidan Huang, Roopal Thakkar, Aileen L. Pangan, Ana P. Lacerda, Julián Panés - Gastroenterology 2020 cited by 317

  20. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

    Authors: William J. Sandborn, Christopher Gasink, Long-Long Gao, Marion Blank, Jewel Johanns, Cynthia Guzzo, Bruce E. Sands, Stephen B. Hanauer, Stephan R. Targan, Paul Rutgeerts, Subrata Ghosh, Willem J.S. de Villiers, Remo Panaccione, Gordon R. Greenberg, Stefan Schreiber, Simon Lichtiger, Brian G. Feagan - New England Journal of Medicine 2012 cited by 1,128

  21. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

    Authors: William J. Sandborn, Geert D’Haens, Walter Reinisch, Julián Panés, Daphne Chan, Susana Gonzalez, Kathleen Weisel, Matthew Germinaro, Mary Ellen Frustaci, Zijiang Yang, Omoniyi J. Adedokun, Chenglong Han, Remo Panaccione, Tadakazu Hisamatsu, Silvio Danese, David T. Rubin, Bruce E. Sands, Anita Afzali, Jane M. Andrews, Brian G. Feagan - Gastroenterology 2022 cited by 198

  22. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

    Authors: Bruce E. Sands, Frank Anderson, Çharles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, Michael A. Kamm, Joshua R. Korzenik, Bret A. Lashner, Jane E. Onken, Daniel Rachmilewitz, Paul Rutgeerts, Gary Wild, Douglas C. Wolf, P Marsters, Suzanne Travers, Marion Blank, S J van Deventer - New England Journal of Medicine 2004 cited by 2,221

  23. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

    Authors: Mahmoud Mosli, Guangyong Zou, Sushil Kumar Garg, Sean Feagan, John K MacDonald, Nilesh Chande, William J. Sandborn, Brian G. Feagan - The American Journal of Gastroenterology 2015 cited by 682

  24. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

    Authors: Simon Travis, Dan Schnell, Piotr Krzeski, María T. Abreu, Douglas G. Altman, Jean–Frédéric Colombel, Brian G. Feagan, Stephen B. Hanauer, Marc Lémann, Gary R. Lichtenstein, Phillippe R Marteau, Walter Reinisch, Bruce E. Sands, Bruce Yacyshyn, Christian A. Bernhardt, Jean‐Yves Mary, William J. Sandborn - Gut 2011 cited by 626